- Dasatinib Inhibits Lyn and Fyn Src-Family Kinases in Mast Cells to Suppress Type I Hypersensitivity in Mice
Dajeong Lee et al, 2020, Biomolecules & Therapeutics CrossRef - Anti-Metastatic Effect of Pyruvate Dehydrogenase Kinase 4 Inhibition in Bladder Cancer via the ERK, SRC, and JNK Pathways
Eun Hye Lee et al, 2022, International Journal of Molecular Sciences CrossRef - Activation of MAPK signalling results in resistance to saracatinib (AZD0530) in ovarian cancer
Niamh McGivern et al, 2018, Oncotarget CrossRef - Mucinous ovarian cancer: current therapeutic targets, preclinical progress, and experimental drugs
Melita Moioli et al, 2019, Expert Opinion on Investigational Drugs CrossRef - Systematic drug sensitivity testing reveals synergistic growth inhibition by dasatinib or mTOR inhibitors with paclitaxel in ovarian granulosa cell tumor cells
Ulla-Maija Haltia et al, 2017, Gynecologic Oncology CrossRef - Dasatinib can enhance paclitaxel and gemcitabine inhibitory activity in human pancreatic cancer cells
Ling Ma et al, 2019, Cancer Biology & Therapy CrossRef - FYN: emerging biological roles and potential therapeutic targets in cancer
SanFei Peng et al, 2023, Journal of Translational Medicine CrossRef - Targeting the Extra-Cellular Matrix—Tumor Cell Crosstalk for Anti-Cancer Therapy: Emerging Alternatives to Integrin Inhibitors
Girieca Lorusso et al, 2020, Frontiers in Oncology CrossRef - Interplay between paclitaxel, gap junctions, and kinases: unraveling mechanisms of action and resistance in cancer therapy
Dong-Oh Moon, 2024, Molecular Biology Reports CrossRef - miR-217 and CAGE form feedback loop and regulates the response to anti-cancer drugs through EGFR and HER2
Youngmi Kim et al, 2016, Oncotarget CrossRef - Paclitaxel-Induced Src Activation Is Inhibited by Dasatinib Treatment, Independently of Cancer Stem Cell Properties, in a Mouse Model of Ovarian Cancer
Elif Kadife et al, 2019, Cancers CrossRef - Comprehensive Analysis of Tumor Microenvironment Identified Prognostic Immune-Related Gene Signature in Ovarian Cancer
Na Li et al, 2021, Frontiers in Genetics CrossRef - Network controllability solutions for computational drug repurposing using genetic algorithms
Victor-Bogdan Popescu et al, 2022, Scientific Reports CrossRef - Utility of a Novel Three-Dimensional and Dynamic (3DD) Cell Culture System for PK/PD Studies: Evaluation of a Triple Combination Therapy at Overcoming Anti-HER2 Treatment Resistance in Breast Cancer
Anusha Ande et al, 2018, Frontiers in Pharmacology CrossRef - Growth inhibitory effect of the Src inhibitor dasatinib in combination with anticancer agents on uterine cervical adenocarcinoma cells
Eri Takiguchi et al, 2017, Experimental and Therapeutic Medicine CrossRef - Deciphering Biophysical Modulation in Ovarian Cancer Cells
Makhdoom Sarwar et al, 2021, Cell Biochemistry and Biophysics CrossRef - Synergistic Anti-Tumor Effect of Palmitoylcarnitine and Dasatinib in Liver Cancer
Ragini Singh et al, 2022, Livers CrossRef - Autophagy targeted nanomedicines and nanotheranostics in cancer imaging and therapy
Nandini Randhave et al, 2024, Journal of Drug Delivery Science and Technology CrossRef - c-Src and EGFR Inhibition in Molecular Cancer Therapy: What Else Can We Improve?
Stefania Belli et al, 2020, Cancers CrossRef - Development of a high-throughput kinase activity platform using nanoLC-MS/MS with DIA approach for studying the anti-cancer mechanism of Taxol in ovarian cancer
Chia-Hsin Lee et al, 2024, Analytica Chimica Acta CrossRef - Impact of the putative cancer stem cell markers and growth factor receptor expression on the sensitivity of ovarian cancer cells to treatment with various forms of small molecule tyrosine kinase inhibitors and cytotoxic drugs
Soozana Puvanenthiran et al, 2016, International Journal of Oncology CrossRef - Mechanisms of Taxane Resistance
Sara M. Maloney et al, 2020, Cancers CrossRef - Doxorubicin delivered by a redox-responsive dasatinib-containing polymeric prodrug carrier for combination therapy
Jingjing Sun et al, 2017, Journal of Controlled Release CrossRef